戈利木单抗治疗复发性葡萄膜炎和强直性脊柱炎:病例报告,致编辑的信

Maysoun Kudsi, Tasneem Drie, Sumaya Dumirieh
{"title":"戈利木单抗治疗复发性葡萄膜炎和强直性脊柱炎:病例报告,致编辑的信","authors":"Maysoun Kudsi, Tasneem Drie, Sumaya Dumirieh","doi":"10.1097/ms9.0000000000002342","DOIUrl":null,"url":null,"abstract":"\n \n Uveitis, as an extra-articular presentation, is found in 23% of patients with Ankylosing Spondylitis and is a challenging disease to treat.\n \n \n \n we presented A 32-year-old male presented to the out-hospital, complaining of recurrent anterior uveitis 8 years earlier in his left eye, and suffered from inflammatory lumber pain for 2 years. so a diagnosis of Ankylosing Spondylitis(AS) after the failure of many therapeutic strategies, 50 mg /month subcutaneous Golimumab was started with clinical remission of AS and uveitis.\n \n \n \n The American College of Rheumatology 10 recommends the use of etanercept and adalimumab in the treatment of recurrent uveitis in AS patients. Similarly, the European League Against Rheumatism11 recommended using Infliximab, Adalimumab, or Certolizumab to prevent the recurrence of uveitis recurrence. Till now, a case about treating refractory uveitis with Golimumab in AS patients was published1.\n \n \n \n Golimumab was found to be effective in the treatment of uveitis associated with spondyloarthritis refractory at least one immunosuppressive drug.\n","PeriodicalId":503882,"journal":{"name":"Annals of Medicine & Surgery","volume":"2 8","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Treatment of recurrent uveitis and ankylosing spondylitis with golimumab: a case report, Letter to Editor\",\"authors\":\"Maysoun Kudsi, Tasneem Drie, Sumaya Dumirieh\",\"doi\":\"10.1097/ms9.0000000000002342\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n \\n Uveitis, as an extra-articular presentation, is found in 23% of patients with Ankylosing Spondylitis and is a challenging disease to treat.\\n \\n \\n \\n we presented A 32-year-old male presented to the out-hospital, complaining of recurrent anterior uveitis 8 years earlier in his left eye, and suffered from inflammatory lumber pain for 2 years. so a diagnosis of Ankylosing Spondylitis(AS) after the failure of many therapeutic strategies, 50 mg /month subcutaneous Golimumab was started with clinical remission of AS and uveitis.\\n \\n \\n \\n The American College of Rheumatology 10 recommends the use of etanercept and adalimumab in the treatment of recurrent uveitis in AS patients. Similarly, the European League Against Rheumatism11 recommended using Infliximab, Adalimumab, or Certolizumab to prevent the recurrence of uveitis recurrence. Till now, a case about treating refractory uveitis with Golimumab in AS patients was published1.\\n \\n \\n \\n Golimumab was found to be effective in the treatment of uveitis associated with spondyloarthritis refractory at least one immunosuppressive drug.\\n\",\"PeriodicalId\":503882,\"journal\":{\"name\":\"Annals of Medicine & Surgery\",\"volume\":\"2 8\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Medicine & Surgery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/ms9.0000000000002342\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Medicine & Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/ms9.0000000000002342","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

葡萄膜炎是强直性脊柱炎的一种关节外表现,在23%的强直性脊柱炎患者中发现,是一种治疗难度很大的疾病。我们介绍了一位32岁的男性患者,主诉8年前左眼复发性前葡萄膜炎,并伴有2年的炎性腰痛,因此被诊断为强直性脊柱炎(AS),在多种治疗策略失败后,开始使用50毫克/月的皮下注射戈利木单抗,强直性脊柱炎和葡萄膜炎临床缓解。 美国风湿病学会(American College of Rheumatology 10)建议使用依那西普(etanercept)和阿达木单抗(adalimumab)治疗强直性脊柱炎患者的复发性葡萄膜炎。同样,欧洲抗风湿病联盟(European League Against Rheumatism)11 也建议使用英夫利西单抗(Infliximab)、阿达木单抗(Adalimumab)或赛妥珠单抗(Certolizumab)来预防葡萄膜炎复发。迄今为止,已有一例 AS 患者使用戈利木单抗治疗难治性葡萄膜炎的病例发表1。 研究发现,戈利木单抗可有效治疗至少一种免疫抑制剂难治的脊柱关节炎相关葡萄膜炎。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Treatment of recurrent uveitis and ankylosing spondylitis with golimumab: a case report, Letter to Editor
Uveitis, as an extra-articular presentation, is found in 23% of patients with Ankylosing Spondylitis and is a challenging disease to treat. we presented A 32-year-old male presented to the out-hospital, complaining of recurrent anterior uveitis 8 years earlier in his left eye, and suffered from inflammatory lumber pain for 2 years. so a diagnosis of Ankylosing Spondylitis(AS) after the failure of many therapeutic strategies, 50 mg /month subcutaneous Golimumab was started with clinical remission of AS and uveitis. The American College of Rheumatology 10 recommends the use of etanercept and adalimumab in the treatment of recurrent uveitis in AS patients. Similarly, the European League Against Rheumatism11 recommended using Infliximab, Adalimumab, or Certolizumab to prevent the recurrence of uveitis recurrence. Till now, a case about treating refractory uveitis with Golimumab in AS patients was published1. Golimumab was found to be effective in the treatment of uveitis associated with spondyloarthritis refractory at least one immunosuppressive drug.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信